Life sciences investment group and part of global investment firm Carlyle, Abingworth announced last week it had exceeded its $300 million target by $56 million.
A not-for-profit organization, Medicines Development for Global Health (MDGH), that develops medicines for neglected diseases in low- and middle-income countries, will benefit from support from contract research organization (CRO), Phastar.
M&G Investments has made a $57 million investment with Swiss-based tech firm, SkyCell and says it is seeking to change the face of international pharma supply chains.
Matteo Lai was part of a panel at DPharm in Boston this year, it was called working together to accelerate the adoption of digital biomarkers in clinical trials.
The Gen AI revolution promises to redefine various industries, with the life sciences sector at the forefront of this transformation. OSP had the chance to speak to Tarun Mathur, CEO at Indegene, who was keen to allay many of the fears those in the industry...
Small molecule drugs are carving a significant niche in lung cancer treatment, according to data and analytics company, GlobalData, and Tagrisso is well on its way to dominating the market.
A new patient-first service that will support sponsors and sites accelerate the development of their therapies has been launched by Innovative Trials yesterday (October 9).
A new generative artificial intelligence (AI) tool has been launched by H1, a global healthcare data company and will have a 'profound impact on clinical trial diversity'.
Contract research organization (CRO), Phastar, has had its net-zero target approved by SBTi which it hopes to achieve by adopting stringent sustainability standards.
A 15-year partnership between Medidata, a Dassault Systèmes company, and the National Cancer Institute (NCI) has been extended by five years. The NCI is part of the National Institutes of Health.
Chinese biopharmaceutical company, Hutchmed Limited, has announced today (Friday September 29) that it has taken a step towards bringing a colon and rectum cancer drug to a third market.
Drug discovery will benefit from a virtual artificial intelligence (AI) expert thanks to Opportunity Pharma and OpenEye, Cadence Molecular Sciences joining forces.
The Japanese firm Astellas Pharma will apply for planning permission to construct a drug manufacturing facility in Tralee, Co. Kerry, Ireland worth around €330 million ($352 million).
CymaBay announced recently the initiation of its 52-week, placebo-controlled, randomized, phase 3 study — 'Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase (ALP) Levels in subjects with Primary Biliary Cholangitis...
Andrew MacGarvey is chief operating officer (COO) of Phastar. We caught up with him earlier in the summer at DIA Global in Boston to discuss the company’s origins, opportunities for big analytical data DCTs, artificial intelligence and machine learning...
A partnership between Banner Health and nference will offer more ‘potent insight generation, offering researchers the option to examine more inclusive data’.
QuantHealth announced it has raised a $15 million series A funding round today (August 22) for its clinical simulator that can predict how a patient will respond to treatment in a clinical trial.
Another company OSP was lucky enough to catch up with at DIA Global in Boston this year, was well-established generative artificial intelligence (AI) software company, Yseop.
Rohit Nambisam is CEO of Lokavant, OSP caught up with him at DIA Global in Boston earlier this summer to find out more about him and the work he is passionate about.
A partnership between technology company Fluree and Vitality TechNet is a ‘groundbreaking effort’ to shorten timelines within the drug discovery process.
LighthouseAI, a company that specializes in compliance solutions for the pharmaceutical supply chain, has announced a $2.25 million seed round, led by Healthy Ventures with participation from Bertelsmann Next.
Nathan Johnson has 20 years’ experience in clinical research as an innovator and programmer with expertise in statistical analysis and reporting, SAS programming, standards development, and data management.
Sigma Mostafa is the chief scientific officer of KBI Biopharma, a development and contract manufacturing organization serving the biopharmaceutical industry.
OSP was fortunate enough to have an interesting discussion with Stephen Corson, who is a statistics manager at Phastar, a specialist biometrics CRO headquartered in the UK.
Updated guidelines for risk-based quality management (RBQM) are much more than just for monitoring purposes and can show quality by design concepts, save immeasurable time on manpower and shows there has been a complete mindset shift within the last 15...
Everybody seems to be talking about artificial intelligence at the moment. Some are fascinated, others afraid and a few might worry for their jobs. However, for the pharmaceutical industry, it is said to be completely transforming the landscape.
Phastar is a specialist biometrics contract research organization offering statistical consulting, clinical trial reporting, data management and data science services and will be providing a presentation and running a workshop to give delegates working...
CluePoints is continuing to invest in artificial intelligence (AI) and machine learning (ML) they say they want to help clients 'extract every drop of potential from the RBQM-driven interrogation of their own datasets'. It says it recognizes...
CDMO Wheeler Bio, Inc. has welcomed Charles River’s flexible biologics testing lab, RightSource, to its Oklahoma City drug substance manufacturing site.
Owlstone Medical has won a contract from the US Department of Defense that will allow it to develop a handheld breath biopsy device for early infectious diseases.
TechBio company, Closed Loop Medicine Ltd, and pharmaceutical company, Pharmanovia have entered into a co-development for precision medicine combination therapeutics.
Exscientia plc has announced a sixth molecule has been created through its generative artificial intelligence (AI) platform to enter clinical stage. It is the third clinical molecule from a collaboration with Sunitomo Pharma to enter phase 1 trials.
Cognizant has announced a platform that can use it consulting, advisory, ecosystem partnership along with digital studios and industry knowledge to help its clients transition to generative artificial intelligence (AI).
Xequel Bio has selected Societal CDMO to support the ongoing clinical development of a patented new chemical entity based on its aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform.
As part of a new initiative, the generic manufacturer will boost access to treatments for anxiety and depression across seven new states across the US, potentially reaching more than 650,000 uninsured patients.
Rich Christie is chief medical officer at AiCure LLC. He is a firm believer in digtal biomarkers and the audio and visual biomarkers that can be captured through a front-facing camera. OSP inteviewed him to find about more about the changing landscape...
